These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 17222673)
1. Immunotherapy for orthotopic murine bladder cancer using bacillus Calmette-Guerin recombinant protein Mpt-64. Yu DS; Lee CF; Chang SY J Urol; 2007 Feb; 177(2):738-42. PubMed ID: 17222673 [TBL] [Abstract][Full Text] [Related]
2. Immunotherapy for bladder cancer using recombinant bacillus Calmette-Guerin DNA vaccines and interleukin-12 DNA vaccine. Lee CF; Chang SY; Hsieh DS; Yu DS J Urol; 2004 Mar; 171(3):1343-7. PubMed ID: 14767345 [TBL] [Abstract][Full Text] [Related]
3. Antitumor effects of recombinant BCG and interleukin-12 DNA vaccines on xenografted murine bladder cancer. Yu DS; Lee CF; Hsieh DS; Chang SY Urology; 2004 Mar; 63(3):596-601. PubMed ID: 15028475 [TBL] [Abstract][Full Text] [Related]
4. Immunodominant PstS1 antigen of mycobacterium tuberculosis is a potent biological response modifier for the treatment of bladder cancer. Sänger C; Busche A; Bentien G; Spallek R; Jonas F; Böhle A; Singh M; Brandau S BMC Cancer; 2004 Nov; 4():86. PubMed ID: 15566565 [TBL] [Abstract][Full Text] [Related]
5. Anti-interleukin-10R1 monoclonal antibody enhances bacillus Calmette-Guérin induced T-helper type 1 immune responses and antitumor immunity in a mouse orthotopic model of bladder cancer. Bockholt NA; Knudson MJ; Henning JR; Maymí JL; Weady P; Smith GJ; Eisenbraun MD; Fraser JD; O'Donnell MA; Luo Y J Urol; 2012 Jun; 187(6):2228-35. PubMed ID: 22503050 [TBL] [Abstract][Full Text] [Related]
6. Treatment of bladder carcinomas using recombinant BCG DNA vaccines and electroporative gene immunotherapy. Lee CF; Chang SY; Hsieh DS; Yu DS Cancer Gene Ther; 2004 Mar; 11(3):194-207. PubMed ID: 14973549 [TBL] [Abstract][Full Text] [Related]
7. Intravesical interleukin-12 gene therapy in an orthotopic bladder cancer model. Horinaga M; Harsch KM; Fukuyama R; Heston W; Larchian W Urology; 2005 Aug; 66(2):461-6. PubMed ID: 16040105 [TBL] [Abstract][Full Text] [Related]
8. Reduction of bladder tumor growth in mice treated with intravesical Bacillus Calmette-Guérin and its correlation with Bacillus Calmette-Guérin viability and natural killer cell activity. Shapiro A; Ratliff TL; Oakley DM; Catalona WJ Cancer Res; 1983 Apr; 43(4):1611-5. PubMed ID: 6339040 [TBL] [Abstract][Full Text] [Related]
11. CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity. Mangsbo SM; Ninalga C; Essand M; Loskog A; Tötterman TH J Immunother; 2008 Jan; 31(1):34-42. PubMed ID: 18157010 [TBL] [Abstract][Full Text] [Related]
13. Interleukin-12 immunotherapy of murine transitional cell carcinoma of the bladder: dose dependent tumor eradication and generation of protective immunity. O'Donnell MA; Luo Y; Hunter SE; Chen X; Hayes LL; Clinton SK J Urol; 2004 Mar; 171(3):1330-5. PubMed ID: 14767343 [TBL] [Abstract][Full Text] [Related]
14. The expression level of ligands for natural killer cell receptors predicts response to bacillus Calmette-Guerin therapy: a pilot study. Yutkin V; Pode D; Pikarsky E; Mandelboim O J Urol; 2007 Dec; 178(6):2660-4. PubMed ID: 17945285 [TBL] [Abstract][Full Text] [Related]